Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Catalyst Pharm Inc (CPRX)

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,766,085
  • Shares Outstanding, K 104,071
  • Annual Sales, $ 140,830 K
  • Annual Income, $ 39,480 K
  • 60-Month Beta 1.27
  • Price/Sales 12.58
  • Price/Cash Flow 43.94
  • Price/Book 6.48
Trade CPRX with:

Options Overview Details

View History
  • Implied Volatility 62.22% ( -0.09%)
  • Historical Volatility 63.32%
  • IV Percentile 33%
  • IV Rank 33.81%
  • IV High 120.90% on 06/17/22
  • IV Low 32.24% on 01/07/22
  • Put/Call Vol Ratio 0.14
  • Today's Volume 587
  • Volume Avg (30-Day) 980
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 0
  • Open Int (30-Day) 8,400

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate 0.20
  • Number of Estimates 5
  • High Estimate 0.22
  • Low Estimate 0.19
  • Prior Year 0.09
  • Growth Rate Est. (year over year) +122.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.35 +27.09%
on 11/03/22
17.76 -4.45%
on 11/23/22
+2.47 (+17.03%)
since 10/25/22
3-Month
11.67 +45.42%
on 09/23/22
17.76 -4.45%
on 11/23/22
+2.63 (+18.34%)
since 08/25/22
52-Week
5.24 +223.85%
on 01/28/22
17.76 -4.45%
on 11/23/22
+9.59 (+129.95%)
since 11/24/21

Most Recent Stories

More News
Corcept (CORT) Up YTD on Robust Korlym Sales, Pipeline Advances

Corcept's (CORT) Cushing's syndrome drug, Korlym, is witnessing higher sales and a strong uptake since its approval. Other pipeline candidates are also advancing well.

MRK : 107.50 (+0.64%)
UTHR : 268.07 (+0.45%)
CORT : 26.10 (+0.42%)
CPRX : 16.97 (-0.35%)
ImmunoGen (IMGN) Gets Accelerated FDA Approval for Ovarian Cancer Drug

ImmunoGen (IMGN) receives accelerated FDA approval for its lead drug mirvetuximab soravtansine-gynx, to be marketed as Elahere. The drug will treat adults with ovarian cancer.

RHHBY : 41.0600 (+1.08%)
IMGN : 5.15 (-0.19%)
CPRX : 16.97 (-0.35%)
ESPR : 6.86 (+1.63%)
FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

CPRX : 16.97 (-0.35%)
ESPR : 6.86 (+1.63%)
IONS : 41.56 (+0.75%)
AMRX : 2.39 (-1.24%)
Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

CPRX : 16.97 (-0.35%)
Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.

CPRX : 16.97 (-0.35%)
DICE : 32.56 (-2.72%)
Here's How Much a $1000 Investment in Catalyst Pharmaceutical Made 10 Years Ago Would Be Worth Today

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

CPRX : 16.97 (-0.35%)
Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?

Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.

NBIX : 122.15 (+2.67%)
MDY : 467.50 (+0.52%)
CPRX : 16.97 (-0.35%)
AVEO : 14.87 (+0.07%)
IMCR : 61.54 (-2.73%)
AMGN : 283.74 (+0.12%)
VRTX : 312.98 (-1.01%)
REGN : 736.23 (+0.12%)
GILD : 86.26 (+0.98%)
Catalyst's (CPRX) Q3 Earnings & Revenues Surpass Estimates

Catalyst's (CPRX) earnings and revenues beat estimates for the third quarter of 2022. The company increases the full-year revenue guidance.

JAZZ : 153.00 (+1.15%)
CPRX : 16.97 (-0.35%)
CANF : 0.8721 (+1.95%)
EXAI : 5.73 (+6.11%)
Catalyst Pharmaceutical (CPRX) Tops Q3 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 5.26% and 6.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CPRX : 16.97 (-0.35%)
ALPN : 6.59 (+5.10%)
Catalyst Pharmaceuticals (CPRX) to Post Q3 Earnings: What's Up?

On Catalyst Pharmaceuticals' (CPRX) third-quarter earnings call, investors will likely focus on the sales performance of Firdapse approved for treating LEMS.

JAZZ : 153.00 (+1.15%)
CPRX : 16.97 (-0.35%)
ITCI : 52.23 (+2.03%)
ESPR : 6.86 (+1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights...

See More

Key Turning Points

3rd Resistance Point 17.86
2nd Resistance Point 17.48
1st Resistance Point 17.23
Last Price 16.97
1st Support Level 16.59
2nd Support Level 16.21
3rd Support Level 15.96

See More

52-Week High 17.76
Last Price 16.97
Fibonacci 61.8% 12.98
Fibonacci 50% 11.50
Fibonacci 38.2% 10.02
52-Week Low 5.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar